Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Toronto
Clinical trial register · Canada

Clinical Trials in Toronto, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Canada and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6567 matching records held by the registry are in this view. Synced 17 Nov 2026, 03:20 UTC
6567
Studies in scope
all four open statuses
3485
Recruiting now
open to new participants
883
Lead sponsors
across recruiting studies
Top sites
Toronto 45 Montreal 27 London 22 Calgary 22 Québec 21

Trials with a site in Toronto

45 of 6567 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Canada
Start
Not yet open
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
NCT07883590Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
Eli Lilly and Company
Phase 1
32
Montreal, Toronto
2026-11
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Montreal, Toronto, Vancouver
2026-05-28
Recruiting
Eli Lilly and Company
Phase 1
32
Calgary, London, Montreal, Toronto
2026-05-14
Recruiting
Eli Lilly and Company
Phase 1
32
Calgary, London, Montreal, Toronto
2026-05-14
Recruiting
Eli Lilly and Company
Phase 2
531
Sarnia, Scarborough, Stouffville, Toronto
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
342
Sarnia, Scarborough, Stouffville, Toronto
2026-04-29
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
Eli Lilly and Company
Phase 2
66
Chicoutimi, London, Ottawa, Richmond Hill, Toronto, Verdun
2026-04-14
Recruiting
Eli Lilly and Company
Phase 4
150
Toronto
2026-03-09
Recruiting
Eli Lilly and Company
Phase 2
465
Calgary, Courtice, Kamloops, Kelowna, Kingston, Mississauga, Penticton, Toronto
2026-02-13
Recruiting
Eli Lilly and Company
Phase 3
800
Calgary, Lévis, Québec, Saint-Laurent, Toronto, Trois-Rivières
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
900
Guelph, Québec, Stouffville, Toronto, Victoriaville
2026-02-09
Active, closed
Eli Lilly and Company
Phase 3
600
Brampton, Courtice, Hamilton, Joliette, London, Québec, Sherbrooke, Toronto
2026-01-24
Recruiting
Eli Lilly and Company
Phase 3
800
Hamilton, Québec, Toronto, Vancouver
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
1,205
Laval, Lévis, Stoney Creek, Toronto, Winnipeg
2025-10-31
Recruiting
Eli Lilly and Company
Phase 3
1,630
Calgary, Hamilton, Montreal, Sherbrooke, Surrey, Toronto
2025-10-22
Recruiting
Eli Lilly and Company
Phase 2
531
Ajax, Hamilton, Kelowna, Montreal, Québec, Richmond, Saint-Laurent, Toronto
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
4,500
Calgary, Chicoutimi, Edmonton, Halifax, London, North Bay, Québec, Toronto
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,000
Kelowna, Lévis, Oakville, Québec, Red Deer, Toronto
2025-09-30
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Hamilton, Montreal, Toronto
2025-08-06
Recruiting
Eli Lilly and Company
Phase 1
36
Calgary, Edmonton, London, Montreal, Toronto
2025-08-05
Active, closed
Eli Lilly and Company
Phase 3
586
Brampton, Hamilton, Sarnia, Sydney, Toronto
2025-05-29
Recruiting
Eli Lilly and Company
Phase 2
200
Brampton, Chicoutimi, Hamilton, Longueuil, Moncton, Sarnia, Toronto, Waterloo
2025-03-28
Active, closed
Eli Lilly and Company
Phase 3
643
Brampton, Burlington, Courtice, Hamilton, Terrebonne, Thunder Bay, Toronto, Trois-Rivières
2025-03-05
Active, closed
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Eli Lilly and Company
Phase 1
630
Ottawa, Toronto
2024-09-12
Active, closed
[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
NCT06229366Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma, Hormone Sensitive Prostate Cancer
Eli Lilly and Company
Phase 1
142
Hamilton, Montreal, Québec, Saguenay, Toronto, Vancouver
2024-04-03
Recruiting
Eli Lilly and Company
Phase 3
90
Halifax, London, Toronto, Vancouver
2024-03-13
Active, closed
Eli Lilly and Company
Phase 3
1,250
Calgary, Edmonton, Brampton, Hamilton, Sarnia, Toronto, Whitby, Montreal
2024-02-21
Active, closed
Eli Lilly and Company
Phase 3
160
Edmonton, Hamilton, Toronto, Chicoutimi
2023-10-16
Recruiting
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
NCT05821959Sensorineural Hearing Loss, Bilateral
Eli Lilly and Company
Phase 3
48
Toronto
2023-09-15
Recruiting
Eli Lilly and Company
Phase 3
595
Calgary, Cobourg, Markham, Surrey, Toronto, Winnipeg
2023-02-27
Recruiting
Eli Lilly and Company
Phase 1
677
Toronto, Vancouver
2023-01-12
Active, closed
Eli Lilly and Company
Phase 3
8,000
Calgary, London, Montreal, Québec, Surrey, Toronto
2022-10-04
Active, closed
Eli Lilly and Company
Phase 1
260
Toronto, Vancouver
2022-05-11
Active, closed
Eli Lilly and Company
Phase 3
925
Toronto
2022-04-14
Active, closed
Eli Lilly and Company
Phase 3
152
Toronto
2021-12-20
Active, closed
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms
Eli Lilly and Company
Phase 1/2
540
Edmonton, Toronto
2021-07-19
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Eli Lilly and Company
Phase 3
150
London, Toronto
2021-05-26
Active, closed
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
NCT04603001Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
Eli Lilly and Company
Phase 1
260
Vancouver, Toronto, Montreal
2020-11-19
Active, closed
Eli Lilly and Company
Phase 3
1,736
Kelowna, Halifax, New Minas, Newmarket, Ottawa, Peterborough, Sarnia, Toronto
2020-06-19
Active, closed
Eli Lilly and Company
Phase 3
261
Edmonton, Toronto
2020-02-17
Active, closed
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT03899792Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
Eli Lilly and Company
Phase 1/2
36
Toronto
2019-06-13
Active, closed
Eli Lilly and Company
Phase 3
5,637
Ottawa, Toronto, Montreal, Québec, Sherbrooke
2017-07-12
Active, closed
Eli Lilly and Company
Phase 3
493
Edmonton, Oshawa, Ottawa, Toronto, Montreal, Québec
2014-11-06
Active, closed
Eli Lilly and Company
Phase 3
453
Calgary, Edmonton, Montreal, Toronto, Vancouver, Winnipeg
2014-10-03
Active, closed
Eli Lilly and Company
Phase 3
669
Calgary, London, Toronto
2014-07-22
Rows per page Showing 1–45 of 45
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Canadian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 November 2026. https://priyalifescience.com/clinical-trials-canada/city/toronto

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Canada and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,567 studies in total at the last sync on 17 Nov 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 45 of those studies with a site in Toronto that also match the filters currently applied.

How many clinical trials are recruiting in Toronto?

24 of the 45 studies on this page are recruiting new participants as of the 17 Nov 2026, 03:20 UTC sync. A further 1 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Toronto), 45 studies
PhaseStudiesRecruitingShare
Phase 3251155.6%
Phase 111624.4%
Phase 26613.3%
Phase 1/2204.4%
Phase 4112.2%

Most active sponsors

Lead sponsors with the most studies (Toronto)
Lead sponsorStudiesRecruiting
Eli Lilly and Company4524
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.